Hindustan Zinc Stock Shines: Momentum Roars as Silver Sparkles
Silver rallies extend to days leading to end of 2025!(Image TRH)
Zinc supply fears and a silver earnings boost power the stock to a 52-week high—but analysts warn the easy money may be made.
By S JHA
Mumbai, December 17, 2025 — Shares of Hindustan Zinc gave gained over 10% in the last five days of trading sessions. The stock has also risen by 20% in the last one month. Analysts claims that a broader sectoral rally is bringing tailwinds in the stock.
Shares of Hindustan Zinc closed at ₹577.50, gaining almost 2% on Wednesday. The stock also hit a 52-week high of ₹585.50 on Wednesday. Shares of Hindustan Zinc are now trading at a PE valuation of 23.
Kolkata-based StockEdge in a note shared on its Telegram channel said: “Zinc rally! Silver surprise! Strong momentum scores.
But stretched valuations tell different story.” It offered a technical perspective on the stock.
The analyst noted that while the shares of Hindustan Zinc are rising, the gain is coming due to zinc prices rising on global supply concerns. It added that the stock enjoys “strong metals-sector momentum.”
“Investor confidence in production stability,” the analyst at StockEdge reasoned for gains in shares of Hindustan Zinc, adding that momentum is clearly on its side.
The StockEdge in its momentum check gave verdict: 1M Momentum: 87/100; 3M Momentum: 80/100; and 6M Momentum: 97/100
“That’s strong bullish momentum across timeframes — trends traders love to track. The real kicker: Silver,” added the analyst. It also stated that “silver now contributes 38% of EBIT” of Hindustan Zinc. “Global silver deficit + price surge = earnings boost,” argued the analyst, adding that the gains in the stock justifies premium valuation vs history.
“Silver is quietly changing the earnings quality story. But valuations are stretched,” it added.
Arguing that Hindustan Zinc is in a “great business”, analysts at StockEdge stressed that the stock is “not exactly cheap.”
On earnings and upside, the nalyst stated: “EPS growth: +22% FY26, +29% FY27; Strong cash flows & ROE (69–85%); analyst upside estimates only 10.5%, below peers; and near-term strength is limited amid long-term rerating.”
(Disclaimer: This article makes no recommendation for buy or sell of shares of any company)
Brokerage Sounds Bullish on Zydus Lifesciences after USFDA Nod
Follow The Raisina Hills on WhatsApp, Instagram, YouTube, Facebook, and LinkedIn